Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
AstraZeneca
AstraZeneca
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
University of Miami
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Eli Lilly and Company
Sichuan Baili Pharmaceutical Co., Ltd.
SOLTI Breast Cancer Research Group
Spanish Breast Cancer Research Group
Dana-Farber Cancer Institute
Jonsson Comprehensive Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Fudan University
UNICANCER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sun Yat-sen University
University of Ulm